A multicenter, international, randomized, placebo controlled, double-blind, parallel group and
event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the
prevention of ischemic stroke in male and female participants aged 18 years and older after an
acute non-cardioembolic ischemic stroke or high-risk TIA
National Leader: Professor Bruce Campbell
Lead HREC: Professor Bruce Campbell
Status: ASTN Endorsed, Site Initiation Visits starting Feb2023
No. of Patients Currently Recruited: 0 No. of Patients Required: 308
Participating Australian Sites:
- Bruce Campbell, Royal Melbourne Hospital, VIC
- Tim Kleinig, Royal Adelaide Hospital, SA
- Dennis Cordato, Liverpool Hospital, NSW
- Carlos Garcia Esperon, John Hunter Hospital, NSW
- Peter Bailey, Gold Coast University Hospital, QLD
- Miriam Priglinger, Royal Nortshore Hospital, NSW
- Ken Butcher, Prince of Wales Hospital, NSW
- Philip Choi, Box Hill Hospital, VIC
- Andrew Moey, Lyell McEwin Hospital, SA
- Michael Devlin, Princess Alexandra Hospital, QLD
- Rohan Grimley, Sunshine Coast University Hospital, QLD
- Ramesh Sahathevan, Grampians Health, Ballarat, VIC
- Andrew Wong, Royal Brisbane & Women’s Hospital, QLD
- Craig Anderson, Royal Prince Alfred Hospital, NSW
- Darshan Ghia, Fiona Stanley Hospital, WA
- Geoff Cloud, The Alfred Hospital, VIC
- Robert Boland-Freitas, Blacktown Hospital, NSW
- Tissa Wijeratne, Western Health, VIC
- Shaloo Singhal, Monash Health, VIC
- Thomas Chemmanam, Sir Charles Gairdner Hospital, WA
- Chong Wong, Westmead Hospital, NSW
- Sameen Haque, Nepean Hospital, NSW
